These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15252316)

  • 1. Current practical applications of diagnostic immunohistochemistry in breast pathology.
    Lerwill MF
    Am J Surg Pathol; 2004 Aug; 28(8):1076-91. PubMed ID: 15252316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review.
    Bonacho T; Rodrigues F; Liberal J
    Biotech Histochem; 2020 Feb; 95(2):71-91. PubMed ID: 31502889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
    Lee AH
    J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry applied to the differential diagnosis between ductal and lobular carcinoma of the breast.
    de Deus Moura R; Wludarski SC; Carvalho FM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):1-12. PubMed ID: 22595945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas.
    Turashvili G; Bouchal J; Ehrmann J; Fridman E; Skarda J; Kolar Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):59-64. PubMed ID: 17690741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology.
    Dewar R; Fadare O; Gilmore H; Gown AM
    Arch Pathol Lab Med; 2011 Apr; 135(4):422-9. PubMed ID: 21466356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic immunohistochemistry of breast epithelial lesions].
    Balaton AJ; Guinebretière JM; Penault-Llorca F
    Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of immunohistochemistry in the evaluation of breast pathology specimens.
    Zhao L; Yang X; Khan A; Kandil D
    Arch Pathol Lab Med; 2014 Jan; 138(1):16-24. PubMed ID: 24377808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarification of criteria for (i +) nodes associated with breast carcinoma.
    Tickman RJ; Wang NP
    Am J Surg Pathol; 2005 Jan; 29(1):136; author reply 136. PubMed ID: 15613871
    [No Abstract]   [Full Text] [Related]  

  • 10. Avoiding "False Positive" and "False Negative" Immunohistochemical Results in Breast Pathology.
    Li Z; Dabbs DJ
    Pathobiology; 2022; 89(5):309-323. PubMed ID: 35249034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myoepithelial cells in lobular carcinoma in situ: distribution and immunophenotype.
    Wang Y; Jindal S; Martel M; Wu Y; Schedin P; Troxell M
    Hum Pathol; 2016 Sep; 55():126-34. PubMed ID: 27195907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of immunohistochemistry to breast lesions.
    Yeh IT; Mies C
    Arch Pathol Lab Med; 2008 Mar; 132(3):349-58. PubMed ID: 18318578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
    Cimino-Mathews A
    Mod Pathol; 2021 Jan; 34(Suppl 1):62-77. PubMed ID: 33110239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias.
    Bratthauer GL; Moinfar F; Stamatakos MD; Mezzetti TP; Shekitka KM; Man YG; Tavassoli FA
    Hum Pathol; 2002 Jun; 33(6):620-7. PubMed ID: 12152161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
    Mardekian SK; Bombonati A; Palazzo JP
    Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
    Paredes J; Lopes N; Milanezi F; Schmitt FC
    Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double immunolabeling with cytokeratin and smooth-muscle actin in confirming early invasive carcinoma of breast.
    Prasad ML; Hyjek E; Giri DD; Ying L; O'Leary JJ; Hoda SA
    Am J Surg Pathol; 1999 Feb; 23(2):176-81. PubMed ID: 9989844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
    Werling RW; Hwang H; Yaziji H; Gown AM
    Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.
    Lacroix-Triki M; Mery E; Voigt JJ; Istier L; Rochaix P
    Virchows Arch; 2003 Jun; 442(6):548-54. PubMed ID: 12712335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.